Literature DB >> 31811270

Treg cell-based therapies: challenges and perspectives.

Caroline Raffin1, Linda T Vo1, Jeffrey A Bluestone2.   

Abstract

Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In this Review, we discuss the biology of Treg cells and describe new efforts in Treg cell engineering to enhance specificity, stability, functional activity and delivery. Finally, we envision that the success of Treg cell therapy in autoimmunity and transplantation will encourage the clinical use of adoptive Treg cell therapy for non-immune diseases, such as neurological disorders and tissue repair.

Entities:  

Mesh：

Year:  2019        PMID： 31811270     DOI： 10.1038/s41577-019-0232-6

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


  206 in total

1.  Extensor indicis proprius transfer for rupture of the extensor pollicis longus tendon.

Authors:  P A Magnussen; F J Harvey; M A Tonkin
Journal:  J Bone Joint Surg Br       Date:  1990-09

2.  Brain tumour presenting as a dislocated shoulder.

Authors:  D S Elliott
Journal:  J Bone Joint Surg Br       Date:  1990-09

3.  Tissue reaction to subcutaneous implantation of a collagen sponge. A histological, ultrastructural, and immunological study.

Authors:  K Anselme; C Bacques; G Charriere; D J Hartmann; D Herbage; R Garrone
Journal:  J Biomed Mater Res       Date:  1990-06

Review 4.  Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier.

Authors:  Jonathan H Esensten; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  J Allergy Clin Immunol       Date:  2018-10-25       Impact factor: 10.793

5.  Treg cells-the next frontier of cell therapy.

Authors:  Jeffrey A Bluestone; Qizhi Tang
Journal:  Science       Date:  2018-10-12       Impact factor: 47.728

Review 6.  Transplant trials with Tregs: perils and promises.

Authors:  Qizhi Tang; Flavio Vincenti
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

7.  Sugar transport in Trypanosoma brucei: a suitable kinetic probe.

Authors:  S Game; G Holman; R Eisenthal
Journal:  FEBS Lett       Date:  1986-01-01       Impact factor: 4.124

8.  Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis.

Authors:  Adam P Kohm; Pamela A Carpentier; Holly A Anger; Stephen D Miller
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

9.  Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.

Authors:  James B Canavan; Cristiano Scottà; Anna Vossenkämper; Rimma Goldberg; Matthew J Elder; Irit Shoval; Ellen Marks; Emilie Stolarczyk; Jonathan W Lo; Nick Powell; Henrieta Fazekasova; Peter M Irving; Jeremy D Sanderson; Jane K Howard; Simcha Yagel; Behdad Afzali; Thomas T MacDonald; Maria P Hernandez-Fuentes; Nahum Y Shpigel; Giovanna Lombardi; Graham M Lord
Journal:  Gut       Date:  2015-02-24       Impact factor: 23.059

Review 10.  Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies.

Authors:  Richard Duggleby; Robert David Danby; J Alejandro Madrigal; Aurore Saudemont
Journal:  Front Immunol       Date:  2018-02-13       Impact factor: 7.561
View more
  112 in total

Review 1.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

2.  Epigenetically modifying the Foxp3 locus for generation of stable antigen-specific Tregs as cellular therapeutics.

Authors:  Shuqiu Chen; Lei Zhang; Yuanlin Ying; Yixuan Wang; Preston R Arnold; Guangchuan Wang; Junhui Li; R Mark Ghobrial; Wenhao Chen; Xiang Xiao; Xian C Li
Journal:  Am J Transplant       Date:  2020-04-05       Impact factor: 8.086

3.  Single-cell analysis of immune repertoires enabled.

Authors:  Stephen P Schoenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

4.  Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor.

Authors:  Ilian A Radichev; Jeongheon Yoon; David W Scott; Kurt Griffin; Alexei Y Savinov
Journal:  Cell Immunol       Date:  2020-09-30       Impact factor: 4.868

5.  Regulatory T Cells for the Induction of Transplantation Tolerance.

Authors:  Weitao Que; Xiao-Kang Li
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Tolerogenic nanoparticles suppress central nervous system inflammation.

Authors:  Jessica E Kenison; Aditi Jhaveri; Zhaorong Li; Nikita Khadse; Emily Tjon; Sara Tezza; Dominika Nowakowska; Agustin Plasencia; Vincent P Stanton; David H Sherr; Francisco J Quintana
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-25       Impact factor: 11.205

7.  TET family dioxygenases and the TET activator vitamin C in immune responses and cancer.

Authors:  Xiaojing Yue; Anjana Rao
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

8.  Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer.

Authors:  Kaisa Cui; Surui Yao; Han Zhang; Mingyue Zhou; Bingxin Liu; Yulin Cao; Bojian Fei; Shenglin Huang; Zhaohui Huang
Journal:  Oncogene       Date:  2021-02-24       Impact factor: 9.867

9.  Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.

Authors:  James C Lee; Sadaf Mehdizadeh; Jennifer Smith; Arabella Young; Ilgiz A Mufazalov; Cody T Mowery; Adil Daud; Jeffrey A Bluestone
Journal:  Sci Immunol       Date:  2020-10-02

Review 10.  Integration of Islet/Beta-Cell Transplants with Host Tissue Using Biomaterial Platforms.

Authors:  Daniel W Clough; Jessica L King; Feiran Li; Lonnie D Shea
Journal:  Endocrinology       Date:  2020-11-01       Impact factor: 4.736
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.